123971-42-6

Basic information

• Product Name: 2-Thiazolecarboxylic acid,4-(4-methoxyphenyl)-
• Synonyms: 2-Thiazolecarboxylic acid,4-(4-methoxyphenyl)-
• CAS NO: 123971-42-6
• Molecular Formula: C₁₁H₉NO₃S
• Molecular Weight: 235.26
• Mol File: 123971-42-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Thiazolecarboxylic acid,4-(4-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazolecarboxylic acid,4-(4-methoxyphenyl)-(123971-42-6)
• EPA Substance Registry System: 2-Thiazolecarboxylic acid,4-(4-methoxyphenyl)-(123971-42-6)

Safety Data

• Hazardous Substances Data: 123971-42-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Thiazolecarboxylic acid, 4-(4-methoxyphenyl)is used as a pharmaceutical intermediate for the synthesis of various organic compounds. Its unique structure allows it to be a building block in the development of new drugs with potential therapeutic properties.
Used in Research and Development:
2-Thiazolecarboxylic acid,4-(4-methoxyphenyl)is also used in research and development in the field of organic chemistry and drug discovery. Its potential biological activity and versatility make it a valuable tool for scientists and researchers working on the development of new pharmaceuticals and organic compounds.
Overall, 2-Thiazolecarboxylic acid, 4-(4-methoxyphenyl)is a versatile chemical compound with potential applications in pharmaceuticals, research, and development. Its unique structure and properties make it a promising candidate for the synthesis of new organic compounds and the development of innovative drugs.

Upstream product

• 2632-13-5 2-Bromo-4'-methoxyacetophenone 
• 886366-42-3 ethyl 4-(4-methoxyphenyl)thiazole-2-carboxylate 

Downstream Products

• 1826-21-7 4-(4-methoxy-phenyl)-thiazole 

Relevant articles and documents

MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF

Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.

Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors

A series of novel 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides were investigated as dipeptidyl peptidase IV (DPP-4) inhibitors. Introduction of a 4-phenylthiazol-2-yl group showed highly potent DPP-4 inhibitory activity. Among various derivatives, (3R)-3-amino-N-(4-(4-phenylthiazol-2-yl)-tetrahydro-2H- thiopyran-4-yl)-4-(2,4,5-trifluorophenyl)butanamide 1,1-dioxide (30) reduced blood glucose excursion in an oral glucose tolerance test by oral administration.